FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

	Check this box if no longer subjec
	to Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name a	2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY]									(Ch	eck all app Direc	tionship of Reporti all applicable) Director		erson(s) to I 10% Ov Other (s	wner					
(Last)	Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023									Officer (give title below) See rem		below)	Бреспу	
339 BIN	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)										
(Street) CAMBRIDGE MA 02139															X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	Rule	Rule 10b5-1(c) Transaction Indication																		
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											ended to			
		Table	l - No	n-Deriva	tive S	ecui	rities	Acq	juired,	Dis	posed of	f, or	Ben	eficia	ally Owr	ned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)					//Year)	Execu	Deemed cution Date, y nth/Day/Year)				ies Acquired (A Of (D) (Instr. 3,			5. Amo Securi Benefi Owned	ties cially I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)		Price	Report Transa	Reported Transaction(s) (Instr. 3 and 4)					
Common	023			S		244 ⁽¹⁾	1) D \$		\$1 <mark>2.</mark> 1	2 318	318,160(2)		D							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any			tion Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4			3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Nun of	ount nber res						

Explanation of Responses:

- 1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
- 2. Includes 290,341 shares underlying RSUs.

Remarks:

Title: Chief Corporate Development Officer

/s/ Brian Adams, as attorney-

06/28/2023

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.